- Home
- GOVX vs AIMD Comparison
GOVX vs AIMD Comparison
Compare GOVX & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- AIMD
- Stock Information
- Founded
- GOVX 2001
- AIMD 1984
- Country
- GOVX United States
- AIMD United States
- Employees
- GOVX N/A
- AIMD N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- AIMD Health Care
- Exchange
- GOVX Nasdaq
- AIMD Nasdaq
- Market Cap
- GOVX 16.8M
- AIMD 16.9M
- IPO Year
- GOVX N/A
- AIMD N/A
- Fundamental
- Price
- GOVX $0.51
- AIMD $2.66
- Analyst Decision
- GOVX Strong Buy
- AIMD
- Analyst Count
- GOVX 3
- AIMD 0
- Target Price
- GOVX $10.67
- AIMD N/A
- AVG Volume (30 Days)
- GOVX 742.0K
- AIMD 42.7K
- Earning Date
- GOVX 11-07-2025
- AIMD 11-14-2025
- Dividend Yield
- GOVX N/A
- AIMD N/A
- EPS Growth
- GOVX N/A
- AIMD N/A
- EPS
- GOVX N/A
- AIMD N/A
- Revenue
- GOVX $6,143,044.00
- AIMD $110,870.00
- Revenue This Year
- GOVX N/A
- AIMD N/A
- Revenue Next Year
- GOVX N/A
- AIMD N/A
- P/E Ratio
- GOVX N/A
- AIMD N/A
- Revenue Growth
- GOVX 1943.07
- AIMD 70.25
- 52 Week Low
- GOVX $0.43
- AIMD $2.00
- 52 Week High
- GOVX $3.88
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- GOVX 39.70
- AIMD 26.81
- Support Level
- GOVX $0.54
- AIMD $3.20
- Resistance Level
- GOVX $0.61
- AIMD $3.43
- Average True Range (ATR)
- GOVX 0.03
- AIMD 0.23
- MACD
- GOVX -0.00
- AIMD -0.11
- Stochastic Oscillator
- GOVX 14.50
- AIMD 5.14
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.